Donor immune cells take on tough leukemia in early trial

NCT ID NCT05580601

Recruiting now Disease control Sponsor: Children's Hospital Medical Center, Cincinnati Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether specially trained immune cells from a half-matched donor can safely treat acute myeloid leukemia (AML) that has come back or not responded to standard treatment. About 20 people aged 2 and older will receive an infusion of these cells. The main goal is to see if the infusion is safe, and the researchers will also check if it helps control the leukemia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cytokine-Induced Memory-Like Natural Killer (CIML-NK) cells from a half-matched donor
What this could lead to: If it works, this could point toward a new treatment option for hard-to-treat AML using the body's own immune cells.
What could go wrong: This is an early Phase 1/2 trial with only 20 people, so it is too small to prove effectiveness. There are risks of infusion reactions or the cells not lasting long enough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Cincinnati Children's Hospital Medical Center
RECRUITING

Cincinnati, Ohio, 45229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.